This is the authors' abstract. We don't add key points for this paper.
Fmoc solid-phase peptide synthesis has been indispensable for the efficient manufacture of research grade peptides and proteins, and peptide APIs. However, the solid-phase approach is still hampered by solubility issues and aggregation of the resin-bound peptide chain, which limits routine access to peptides > 40 amino acids in length. The use of backbone amide protecting groups, such as through the introduction of N-benzyl-based moieties and pseudoproline dipeptides, ameliorates this synthetic inefficiency somewhat. But benzyl groups can be difficult to remove postassembly, and pseudoprolines are limited to serine, threonine, and cysteine-rich peptide segments. To enhance the utility of backbone protection, we have evaluated the tetrahydropyranyl (Thp) group as a more acid labile alternative to benzyl protection. The Thp group can be efficiently introduced to the resin-bound peptide as a protected dipeptide and is readily cleaved and scavenged postsynthesis. A drastic improvement in the solid-phase assembly of aggregation-prone amyloid-β and prion-derived peptide fragments is observed using Thp as a backbone protecting group. We envisage that Thp-protected dipeptides will become useful building blocks for peptide manufacturing, complementing existing backbone protecting group strategies.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Paravizzini et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: